Reprint

Neurotransmitter-Related Molecular Modeling Studies

Edited by
June 2022
188 pages
  • ISBN978-3-0365-4277-5 (Hardback)
  • ISBN978-3-0365-4278-2 (PDF)

This book is a reprint of the Special Issue Neurotransmitter-Related Molecular Modeling Studies that was published in

Chemistry & Materials Science
Medicine & Pharmacology
Summary

This book focuses of the neurotransmission phenomenon. By definition, neurotransmitters are chemicals that enable communication, i.e., the flow of nerve impulses between nerve cells or between nerve cells and muscles and glands. Recently, one can distinguish excitatory and inhibitory mediators, both of which are endo–exogenous compounds that control the function of the whole organism. From a chemical point of view, neurotransmitters belong to many different structural groups, such as amino acids (such as glycine), peptides (such as substance P, somatostatin), monoamines (such as noradrenaline or dopamine), purine derivatives (such as adenosine), gases (such as nitrogen, NO, carbon monoxide CO), and acetylcholine. From a medical point of view, disturbances in the concentration of neurotransmitters in the body result in the occurrence of mental disorders and diseases (such as depression, schizophrenia, Parkinson’s disease) and contribute to the occurrence of dementia (including Alzheimer’s disease), among other diseases. However, the problem is much wider. These disorders can lead to a number of cardiovascular diseases and can lead to the development of vascular diseases of the brain as well as in many other organs. Therefore, pharmacological intervention is a therapy that tries to interfere with regulatory processes year after year. Such treatments improve survival, reduce the frequency of readmission, and improve patients' quality of life.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
white matter hyperintensities; dysautonomia; genetic polymorphisms; dementia; levodopa; renin-angiotensin system; orthostatic hypotension; reserpine-induced fibromyalgia model; vortioxetine; ropinirole; serotonin and dopamine in fibromyalgia; mouse; dopamine; acetylcholine; glutamate; BDNF; serotonin; neurotransmitters; statins; neurodegenerative diseases; stroke; depression; androgenetic alopecia; 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; mixed dyslipidemia; risk factors; halogenated pyrazolines; monoamine oxidase inhibitors; kinetics; reversibility; molecular dynamics; guanylate cyclase (GC); chronic heart failure (CHF); pulmonary arterial hypertension (PAH); tiagabine; cardiac voltage-gated ion channels; molecular modeling; ECG study; SGLT2i; sodium-glucose cotransporter 2 inhibitors; neuroprotection; atheroprotection; mTOR; type 2 diabetes mellitus; cognitive impairment; inflammation; oxidative stress; antibiotics; neurotoxicity; adverse drug reaction; neurotransmission; serotonin; 5-HT receptors; gastrointestinal tract